Domperidone-Induced QT Prolongation: Add Another Drug to the List

Journal of Pediatrics

Volumn 153, Issue 5, 2008, Pages 596-598

  Collins, Kathryn K ^a   Sondheimer, Judith M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOMPERIDONE; CISAPRIDE; DOPAMINE RECEPTOR BLOCKING AGENT;

CARDIOVASCULAR RISK; DRUG EFFICACY; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERPROLACTINEMIA; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; TORSADE DES POINTES; ANIMAL; DRUG EFFECT; DRUG THERAPY; HEART CONTRACTION; LONG QT SYNDROME; NOTE; RISK; RISK FACTOR;

ANIMALS; CISAPRIDE; DOMPERIDONE; DOPAMINE ANTAGONISTS; DRUG THERAPY; GASTROESOPHAGEAL REFLUX; HUMANS; LONG QT SYNDROME; MYOCARDIAL CONTRACTION; RISK; RISK FACTORS; TORSADES DE POINTES;

EID: 55549144007     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2008.06.009     Document Type: Editorial

References (18)

1. Kannankeril P.J. Understanding drug-induced torsades de pointes: a genetic stance. Expert Opin Drug Saf 7 (2008) 231-239
2. Gupta A., Lawrence A.T., Krishnan K., Kavinsky C.J., and Trohman R.G. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 153 (2007) 891-899
3. Zeltser D., Justo D., Halkin A., Prokhorov V., Heller K., and Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 82 (2003) 282-290
4. Djeddi D., Kongolo G., Lefaix C., Moundard J., and Leke A. Effect of domperidone on QT interval in neonates. J Pediatr 153 (2008) 663-666
5. Drolet B., Rousseau G., Daleau P., Cardinal R., and Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 102 (2000) 1883-1885
6. Rocha C.M., and Barbosa M.M. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 26 (2005) 720-723
7. Wysowski D.K., Corken A., Gallo-Torres H., Talarico L., and Rodriguez E.M. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 96 (2001) 1698-1703
8. Hill S.L., Evangelista J.K., Pizzi A.M., Mobassaleh M., Fulton D.R., and Berul C.I. Proarrhythmia associated with cisapride in children. Pediatrics 101 (1998) 1053-1056
9. Khongphatthanayothin A., Lane J., Thomas D., Yen L., Chang D., and Bubolz B. Effects of cisapride on QT interval in children. J Pediatr 133 (1998) 51-56
10. Bruera E., Villamayor R., Roca E., Barugel M., Tronge J., and Chacon R. Q-T interval prolongation and ventricular fibrillation with IV domperidone. Cancer Treat Rep 70 (1986) 545-546
11. Giaccone G., Bertetto O., and Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet 2 8415 (1984) 1336-1337
12. Vetter V.L., Elia J., Erickson C., Berger S., Blum N., Uzark K., et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117 (2008) 2407-2423
13. Chan A., Isbister G.K., Kirkpatrick C.M., and Dufful S.B. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM 100 (2007) 609-615
14. Augood C., MacLennan S., Gilbert R., and Logan S. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev 4 (2003) CD002300
15. Craig W.R., Hanlon-Dearman A., Sinclair C., Taback S., and Moffatt M. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database Syst Rev 4 (2004) CD003502
16. Dalby-Payne J.R., Morris A.M., and Craig J.C. Meta-analysis of randomized controlled trials on the benefits and risks of using cisapride for the treatment of gastroesophageal reflux in children. J Gastroenterol Hepatol 18 (2003) 196-202
17. Pritchard D.S., Baber N., and Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children?. Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 59 (2005) 725-729
18. Shafrir Y., Levy Y., Ben-Amitai D., Nitzan M., and Steinherz R. Oculogyric crisis due to domperidone therapy. Helv Paediatr Acta 40 (1985) 95